NASDAQ:EOLS - Evolus Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$19.36 +2.47 (+14.62 %)
(As of 05/24/2018 06:16 AM ET)
Previous Close$16.89
Today's Range$16.63 - $19.6969
52-Week Range$6.75 - $19.70
Volume489,046 shs
Average Volume487,478 shs
Market Capitalization$399.29 million
P/E Ratio-71.70
Dividend YieldN/A
BetaN/A

About Evolus (NASDAQ:EOLS)

Evolus logoEvolus, Inc. provides medical aesthetic products for physicians and their patients in the United States. It offers DWP-450, an injectable 900 kilodalton botulinum toxin type A complex designed to address the needs of the facial aesthetics market. The company was founded in 2012 and is headquartered in Irvine, California.

Receive EOLS News and Ratings via Email

Sign-up to receive the latest news and ratings for EOLS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:EOLS
CUSIPN/A
Phone949-284-4555

Debt

Debt-to-Equity RatioN/A
Current Ratio13.84
Quick Ratio13.84

Price-To-Earnings

Trailing P/E Ratio-71.70
Forward P/E Ratio-11.13
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.20 per share
Price / Book8.80

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees21
Outstanding Shares23,640,000

Evolus (NASDAQ:EOLS) Frequently Asked Questions

What is Evolus' stock symbol?

Evolus trades on the NASDAQ under the ticker symbol "EOLS."

How were Evolus' earnings last quarter?

Evolus (NASDAQ:EOLS) announced its quarterly earnings data on Thursday, March, 29th. The company reported $0.24 earnings per share for the quarter. View Evolus' Earnings History.

What price target have analysts set for EOLS?

4 Wall Street analysts have issued 12 month price objectives for Evolus' stock. Their forecasts range from $20.00 to $25.00. On average, they expect Evolus' share price to reach $22.50 in the next twelve months. View Analyst Ratings for Evolus.

What are Wall Street analysts saying about Evolus stock?

Here are some recent quotes from research analysts about Evolus stock:
  • 1. Mizuho analysts commented, "We lowered our estimates and pushed out the forecast (U.S. launch in 3Q:19 vs. 1Q:19 previously), driving a PT reduction to $16 from $21. Reiterate Buy." (5/16/2018)
  • 2. According to Zacks Investment Research, "Evolus, Inc. is a medical aesthetics company. It focuses on providing physicians and patients in aesthetic procedures and treatments. The company focuses on the self-pay aesthetic market and its lead product candidate, DWP-450, is an injectable 900 kDa purified botulinum toxin type A complex. Evolus, Inc. is based in Irvine, California. " (5/15/2018)
  • 3. Cantor Fitzgerald analysts commented, "We spoke with an aesthetic dermatologist today to get his views on how the potential approval of less expensive and/or longer acting toxins could change the existing market. Based on our discussion, we see an opportunity for new toxins such as EOLS’s (OW) DWP-450 and RVNC’s (OW) RT002 to take meaningful market share for AGN’s (N) Botox as well as grow the entire market." (4/25/2018)

Who are some of Evolus' key competitors?

Who are Evolus' key executives?

Evolus' management team includes the folowing people:
  • Mr. Murthy V. Simhambhatla Ph.D., Pres, CEO & Director (Age 52)
  • Mr. Kris Garcia, VP of Fin.
  • Dr. J. Christopher Marmo Ph.D., Chief Operating Officer (Age 49)
  • Jeffrey J. Plumer, VP of Legal
  • Ms. September Riharb, VP of Marketing

When did Evolus IPO?

(EOLS) raised $65 million in an IPO on Thursday, February 8th 2018. The company issued 5,000,000 shares at a price of $12.00-$14.00 per share. Cantor and Mizuho Securities acted as the underwriters for the IPO and SunTrust Robinson Humphrey and JMP Securities were co-managers.

Has Evolus been receiving favorable news coverage?

Media headlines about EOLS stock have been trending somewhat positive on Thursday, Accern Sentiment reports. Accern identifies positive and negative media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Evolus earned a news sentiment score of 0.17 on Accern's scale. They also gave media coverage about the company an impact score of 48.10 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near future.

Who are Evolus' major shareholders?

Evolus' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (0.80%), Citadel Advisors LLC (0.73%), Landscape Capital Management L.L.C. (0.30%), Northern Trust Corp (0.24%), Dean Capital Investments Management LLC (0.15%) and California Public Employees Retirement System (0.14%). View Institutional Ownership Trends for Evolus.

Which major investors are buying Evolus stock?

EOLS stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Citadel Advisors LLC, Landscape Capital Management L.L.C., Northern Trust Corp, Dean Capital Investments Management LLC, California Public Employees Retirement System and Mizuho Securities USA LLC. View Insider Buying and Selling for Evolus.

How do I buy shares of Evolus?

Shares of EOLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Evolus' stock price today?

One share of EOLS stock can currently be purchased for approximately $19.36.

How big of a company is Evolus?

Evolus has a market capitalization of $399.29 million. The company earns $-4,480,000.00 in net income (profit) each year or ($0.27) on an earnings per share basis. Evolus employs 21 workers across the globe.

How can I contact Evolus?

Evolus' mailing address is 17901 Von Karman Avenue Suite 150, Irvine CA, 92614. The company can be reached via phone at 949-284-4555 or via email at [email protected]


MarketBeat Community Rating for Evolus (EOLS)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  35 (Vote Outperform)
Underperform Votes:  28 (Vote Underperform)
Total Votes:  63
MarketBeat's community ratings are surveys of what our community members think about Evolus and other stocks. Vote "Outperform" if you believe EOLS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EOLS will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Evolus (NASDAQ:EOLS) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for Evolus in the last 12 months. Their average twelve-month price target is $22.50, suggesting that the stock has a possible upside of 16.22%. The high price target for EOLS is $25.00 and the low price target for EOLS is $20.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyN/AN/A
Consensus Rating Score: 3.003.00N/AN/A
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $22.50$22.50N/AN/A
Price Target Upside: 16.22% upside137.84% upsideN/AN/A

Evolus (NASDAQ:EOLS) Consensus Price Target History

Price Target History for Evolus (NASDAQ:EOLS)

Evolus (NASDAQ:EOLS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/16/2018MizuhoReiterated RatingBuyHighView Rating Details
4/25/2018Cantor FitzgeraldReiterated RatingBuy$25.00HighView Rating Details
3/5/2018JMP SecuritiesInitiated CoverageMkt Outperform ➝ Outperform$20.00MediumView Rating Details
3/5/2018SunTrust BanksInitiated CoverageBuy ➝ Buy$24.00 ➝ $24.00MediumView Rating Details
(Data available from 5/24/2016 forward)

Earnings

Evolus (NASDAQ:EOLS) Earnings History and Estimates Chart

Earnings by Quarter for Evolus (NASDAQ:EOLS)

Evolus (NASDAQ:EOLS) Earnings Estimates

2018 EPS Consensus Estimate: ($1.61)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.36)($0.36)($0.36)
Q2 20181($0.37)($0.37)($0.37)
Q3 20181($0.45)($0.45)($0.45)
Q4 20181($0.43)($0.43)($0.43)

Evolus (NASDAQ EOLS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/29/2018Q4 2017$0.24ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Evolus (NASDAQ:EOLS) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Evolus (NASDAQ EOLS) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 18.80%
Insider Trading History for Evolus (NASDAQ:EOLS)
Insider Trading History for Evolus (NASDAQ:EOLS)

Evolus (NASDAQ EOLS) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Evolus (NASDAQ EOLS) News Headlines

Source:
DateHeadline
Evolus (EOLS) Forecasted to Post Q2 2018 Earnings of ($0.37) Per ShareEvolus (EOLS) Forecasted to Post Q2 2018 Earnings of ($0.37) Per Share
www.americanbankingnews.com - May 21 at 1:06 AM
Evolus (EOLS) Presents At Bank Of America Merrill Lynch 2018 Healthcare Conference - SlideshowEvolus (EOLS) Presents At Bank Of America Merrill Lynch 2018 Healthcare Conference - Slideshow
seekingalpha.com - May 18 at 3:25 PM
Equities Analysts Offer Predictions for Evolus FY2020 Earnings (EOLS)Equities Analysts Offer Predictions for Evolus' FY2020 Earnings (EOLS)
www.americanbankingnews.com - May 18 at 8:41 AM
Botox Knock Off Could Change Fortunes For EvolusBotox Knock Off Could Change Fortunes For Evolus
seekingalpha.com - May 17 at 3:22 PM
Evolus (EOLS) Stock Rating Reaffirmed by MizuhoEvolus (EOLS) Stock Rating Reaffirmed by Mizuho
www.americanbankingnews.com - May 16 at 9:24 PM
Evolus Announces Progress with DWP-450 Regulatory SubmissionsEvolus Announces Progress with DWP-450 Regulatory Submissions
globenewswire.com - May 16 at 3:22 PM
Evolus (EOLS) Receives CRL Related to BLA for DWP-450Evolus (EOLS) Receives CRL Related to BLA for DWP-450
www.streetinsider.com - May 16 at 3:22 PM
Why Evolus, Inc. Is Crashing TodayWhy Evolus, Inc. Is Crashing Today
finance.yahoo.com - May 16 at 3:22 PM
Evolus (EOLS) to Provide Regulatory Update TodayEvolus (EOLS) to Provide Regulatory Update Today
www.streetinsider.com - May 16 at 3:22 PM
Evolus investors frown as FDA declines to approve Botox rivalEvolus investors frown as FDA declines to approve Botox rival
www.reuters.com - May 16 at 3:22 PM
Mid-Day Market Update: Abaxis Climbs On Acquisition News; Evolus Shares PlungeMid-Day Market Update: Abaxis Climbs On Acquisition News; Evolus Shares Plunge
feeds.benzinga.com - May 16 at 12:55 PM
FDA rejects Evolus marketing application for prabotulinumtoxinA; shares haltedFDA rejects Evolus marketing application for prabotulinumtoxinA; shares halted
seekingalpha.com - May 16 at 9:18 AM
Evolus conference call at 8:30 am ET to discuss U.S. regulatory status of prabotulinumtoxinAEvolus conference call at 8:30 am ET to discuss U.S. regulatory status of prabotulinumtoxinA
seekingalpha.com - May 16 at 8:30 AM
Evolus to Provide Regulatory Update on Wednesday, May 16, 2018Evolus to Provide Regulatory Update on Wednesday, May 16, 2018
finance.yahoo.com - May 16 at 8:30 AM
Evolus (EOLS) Rating Lowered to Hold at Zacks Investment ResearchEvolus (EOLS) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - May 15 at 10:58 PM
FDA action date today for Evolus competitor to BOTOX; shares up 5%FDA action date today for Evolus' competitor to BOTOX; shares up 5%
seekingalpha.com - May 15 at 3:25 PM
Evolus: Is The Botox Knock Off Finally Here?Evolus: Is The Botox Knock Off Finally Here?
seekingalpha.com - May 14 at 3:22 PM
FY2020 Earnings Estimate for Evolus (EOLS) Issued By SunTrust BanksFY2020 Earnings Estimate for Evolus (EOLS) Issued By SunTrust Banks
www.americanbankingnews.com - May 14 at 4:51 AM
Evolus (EOLS) Expected to Announce Earnings of -$0.41 Per ShareEvolus (EOLS) Expected to Announce Earnings of -$0.41 Per Share
www.americanbankingnews.com - May 13 at 8:56 AM
Evolus Reports First Quarter 2018 Financial ResultsEvolus Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 11 at 8:12 AM
Evolus (EOLS) Names David Moatazedi President and CEOEvolus (EOLS) Names David Moatazedi President and CEO
www.streetinsider.com - May 8 at 3:22 PM
Evolus (EOLS) Given Average Rating of "Buy" by BrokeragesEvolus (EOLS) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - May 7 at 11:08 PM
Evolus (EOLS) Upgraded by Zacks Investment Research to BuyEvolus (EOLS) Upgraded by Zacks Investment Research to Buy
www.americanbankingnews.com - May 7 at 10:36 PM
Evolus to Present at the Bank of America Merrill Lynch 2018 Health Care ConferenceEvolus to Present at the Bank of America Merrill Lynch 2018 Health Care Conference
finance.yahoo.com - May 3 at 8:15 AM
Zacks: Evolus (EOLS) Given $22.50 Average Target Price by BrokeragesZacks: Evolus (EOLS) Given $22.50 Average Target Price by Brokerages
www.americanbankingnews.com - April 27 at 5:28 AM
Evolus (EOLS) Expected to Announce Earnings of -$0.36 Per ShareEvolus (EOLS) Expected to Announce Earnings of -$0.36 Per Share
www.americanbankingnews.com - April 25 at 7:16 PM
Evolus (EOLS) Buy Rating Reaffirmed at Cantor FitzgeraldEvolus' (EOLS) Buy Rating Reaffirmed at Cantor Fitzgerald
www.americanbankingnews.com - April 25 at 4:34 PM
Mizuho Reaffirms Buy Rating for Evolus (EOLS)Mizuho Reaffirms Buy Rating for Evolus (EOLS)
www.americanbankingnews.com - April 19 at 11:46 AM
 Evolus (EOLS) Given Consensus Rating of "Strong Buy" by Analysts Evolus (EOLS) Given Consensus Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - April 12 at 7:25 PM
FY2019 EPS Estimates for Evolus Inc (EOLS) Increased by AnalystFY2019 EPS Estimates for Evolus Inc (EOLS) Increased by Analyst
www.americanbankingnews.com - April 9 at 2:28 AM
Evolus Inc (EOLS) Expected to Post Earnings of -$0.36 Per ShareEvolus Inc (EOLS) Expected to Post Earnings of -$0.36 Per Share
www.americanbankingnews.com - April 8 at 9:17 PM
Your Daily Pharma Scoop: Conatus Setback, Applied DNA Signs Agreement, Evolus Announces Results From Late-Stage StudyYour Daily Pharma Scoop: Conatus Setback, Applied DNA Signs Agreement, Evolus Announces Results From Late-Stage Study
seekingalpha.com - April 6 at 3:21 PM
Evolus prabotulinumtoxinA 90 kDa on par with Allergans Botox in late-stage studyEvolus' prabotulinumtoxinA 90 kDa on par with Allergan's Botox in late-stage study
seekingalpha.com - April 5 at 8:54 AM
Evolus (EOLS) Says Phase III European - Canadian Head-to-Head Trial of prabotulinumtoxinA Compared to Botox Met Primary EndpointEvolus (EOLS) Says Phase III European - Canadian Head-to-Head Trial of prabotulinumtoxinA Compared to Botox Met Primary Endpoint
www.streetinsider.com - April 5 at 8:54 AM
Evolus Phase III European - Canadian Head-to-Head Trial of prabotulinumtoxinA Compared to Botox® Meets Primary EndpointEvolus Phase III European - Canadian Head-to-Head Trial of prabotulinumtoxinA Compared to Botox® Meets Primary Endpoint
finance.yahoo.com - April 5 at 8:54 AM
Evolus (EOLS) Raised to "Hold" at ValuEngineEvolus (EOLS) Raised to "Hold" at ValuEngine
www.americanbankingnews.com - April 3 at 4:16 PM
Evolus Inc (EOLS) Short Interest UpdateEvolus Inc (EOLS) Short Interest Update
www.americanbankingnews.com - March 31 at 2:56 AM
Evolus Reports Fourth Quarter and Full Year 2017 Financial ResultsEvolus Reports Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - March 29 at 3:19 PM
Zacks: Evolus Inc (EOLS) Given Consensus Rating of "Strong Buy" by BrokeragesZacks: Evolus Inc (EOLS) Given Consensus Rating of "Strong Buy" by Brokerages
www.americanbankingnews.com - March 28 at 7:18 PM
Zacks: Evolus Inc (EOLS) Given Average Rating of "Strong Buy" by AnalystsZacks: Evolus Inc (EOLS) Given Average Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - March 25 at 7:26 PM
Zacks: Evolus Inc (EOLS) Receives Consensus Recommendation of "Strong Buy" from BrokeragesZacks: Evolus Inc (EOLS) Receives Consensus Recommendation of "Strong Buy" from Brokerages
www.americanbankingnews.com - March 21 at 3:32 AM
Evolus Incs (EOLS) Quiet Period To End  on March 20thEvolus Inc's (EOLS) Quiet Period To End on March 20th
www.americanbankingnews.com - March 13 at 1:10 AM
Evolus Inc (EOLS) Forecasted to Post FY2017 Earnings of ($0.55) Per ShareEvolus Inc (EOLS) Forecasted to Post FY2017 Earnings of ($0.55) Per Share
www.americanbankingnews.com - March 8 at 6:30 AM
Analysts Set Expectations for Evolus Incs FY2017 Earnings (EOLS)Analysts Set Expectations for Evolus Inc's FY2017 Earnings (EOLS)
www.americanbankingnews.com - March 7 at 7:26 AM
Head-To-Head Comparison: Evolus (EOLS) and Its RivalsHead-To-Head Comparison: Evolus (EOLS) and Its Rivals
www.americanbankingnews.com - March 7 at 3:10 AM
 Evolus Inc (EOLS) Given $21.67 Average Target Price by Brokerages Evolus Inc (EOLS) Given $21.67 Average Target Price by Brokerages
www.americanbankingnews.com - March 6 at 11:51 AM
Evolus (EOLS) Now Covered by Analysts at Cantor FitzgeraldEvolus (EOLS) Now Covered by Analysts at Cantor Fitzgerald
www.americanbankingnews.com - March 5 at 9:28 PM
Evolus (EOLS) Now Covered by Analysts at JMP SecuritiesEvolus (EOLS) Now Covered by Analysts at JMP Securities
www.americanbankingnews.com - March 5 at 1:58 PM
Mizuho Initiates Coverage on Evolus (EOLS)Mizuho Initiates Coverage on Evolus (EOLS)
www.americanbankingnews.com - March 5 at 12:58 PM
Evolus (EOLS) Coverage Initiated by Analysts at SunTrust BanksEvolus (EOLS) Coverage Initiated by Analysts at SunTrust Banks
www.americanbankingnews.com - March 5 at 11:49 AM

SEC Filings

Evolus (NASDAQ:EOLS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Evolus (NASDAQ EOLS) Stock Chart for Thursday, May, 24, 2018

Loading chart…

This page was last updated on 5/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.